Differential responses to 223Ra and Alpha-particles exposure in prostate cancer driven by mitotic catastrophe

Autor: Francisco D. C. Guerra Liberal, Hugo Moreira, Kelly M. Redmond, Joe M. O’Sullivan, Ali H. D. Alshehri, Timothy C. Wright, Victoria L. Dunne, Caoimhghin Campfield, Sandra Biggart, Stephen J. McMahon, Kevin M. Prise

Publikováno v: Frontiers in Oncology, Vol 12 (2022)

IntroductionRadium-223 (223Ra) has been shown to have an overall survival benefit in metastatic castration-resistant prostate cancer (mCRPC) involving bone. Despite its increased clinical usage, relatively little is known regarding the mechanism of a

Externí odkaz: https://doaj.org/article/c036d2a956814f3e95393de65eb7ca6f

Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells

Autor: Francesca Amoroso, Kimberley Glass, Reema Singh, Francisco Liberal, Rebecca E. Steele, Sarah Maguire, Rohinton Tarapore, Joshua E. Allen, Sandra Van Schaeybroeck, Karl T. Butterworth, Kevin Prise, Joe M. O’Sullivan, Suneil Jain, David J. Waugh, Ian G. Mills

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)

Abstract Prostate cancer (PCa) is the most common non-cutaneous cancer in men and a notable cause of cancer mortality when it metastasises. The unfolded protein response (UPR) can be cytoprotective but when acutely activated can lead to cell death. I

Externí odkaz: https://doaj.org/article/e08cdcf6c9974257a805988e30144259

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Autor: Axel Heidenreich, Silke Gillessen, Daniel Heinrich, Daniel Keizman, Joe M. O’Sullivan, Joan Carles, Manfred Wirth, Kurt Miller, John Reeves, Monica Seger, Sten Nilsson, Fred Saad

Publikováno v: BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)

Abstract Background Radium-223, a targeted alpha therapy, is used to treat symptomatic patients with castration-resistant prostate cancer (CRPC) and bone metastases. Data for radium-223 in asymptomatic CRPC patients with bone metastases are lacking.

Externí odkaz: https://doaj.org/article/3f5f9262102d4e0b9bb48d46e0969ebd

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Autor: Gerhardt Attard, Laura Murphy, Noel W Clarke, Ashwin Sachdeva, Craig Jones, Alex Hoyle, William Cross, Robert J Jones, Christopher C Parker, Silke Gillessen, Adrian Cook, Chris Brawley, Clare Gilson, Hannah Rush, Hoda Abdel-Aty, Claire L Amos, Claire Murphy, Simon Chowdhury, Zafar Malik, J Martin Russell, Nazia Parkar, Cheryl Pugh, Carlos Diaz-Montana, Carmel Pezaro, Warren Grant, Helen Saxby, Ian Pedley, Joe M O'Sullivan, Alison Birtle, Joanna Gale, Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzouebi, Omi Parikh, Angus Robinson, Amir H Montazeri, James Wylie, Anjali Zarkar, Richard Cathomas, Michael D Brown, Yatin Jain, David P Dearnaley, Malcolm D Mason, Duncan Gilbert, Ruth E Langley, Robin Millman, David Matheson, Matthew R Sydes, Louise C Brown, Mahesh K B Parmar, Nicholas D James, Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, Dakshinamoorthy Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, Mohammed Kagzi, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan McLaren, Nishi Gupta, Stergios Boussios, Henry Taylor, John Graham, Carla Perna, Lucinda Melcher, Ami Sabharwal, Uschi Hofmann, Robert Dealey, Neil McPhail, Robert Brierly, Lisa Capaldi, Norma Sidek, Peter Whelan, Peter Robson, Alison Falconer, Sarah Rudman, Sindu Vivekanandan, Vinod Mullessey, Maria Vilarino-Varela, Vincent Khoo, Karen Tipples, Mehran Afshar, Patryk Brulinski, Vijay Sangar, Clive Peedell, Ashraf Azzabi, Peter Hoskin, Viwod Mullassery, Santhanam Sundar, Yakhub Khan, Ruth Conroy, Andrew Protheroe, Judith Carser, Paul Rogers, Kathryn Tarver, Stephanie Gibbs, Mohammad Muneeb Khan, Mohan Hingorani, Simon Crabb, Manal Alameddine, Neeraj Bhalla, Robert Hughes, John Logue, Darren Leaning, Salil Vengalil, Daniel Ford, Georgina Walker, Ahmed Shaheen, Omar Khan, Andrew Chan, Imtiaz Ahmed, Serena Hilman, Ian Sayers, Ashok Nikapota, David Bloomfield, Tim Porter, Joji Joseph, Cyrill Rentsch, Ricardo Pereira Mestre, Enrico Roggero, Jörg Beyer, Markus Borner, Raeto Strebel, Dominik Berthold, Daniel Engeler, Hubert John, Razvan Popescu, Donat Durr

Publikováno v: STAMPEDE investigators, Attard, G, Murphy, L, Clarke, N W, Sachdeva, A, Jones, C, Hoyle, A, Cross, W, Jones, R J, Parker, C C, Gillessen, S, Cook, A, Brawley, C, Gilson, C, Rush, H, Abdel-Aty, H, Amos, C L, Murphy, C, Chowdhury, S, Malik, Z, Russell, J M, Parkar, N, Pugh, C, Diaz-Montana, C, Pezaro, C, Grant, W, Saxby, H, Pedley, I, O'Sullivan, J M, Birtle, A, Gale, J, Srihari, N, Thomas, C, Tanguay, J, Wagstaff, J, Das, P, Gray, E, Alzouebi, M, Parikh, O, Robinson, A, Montazeri, A H, Wylie, J, Zarkar, A, Cathomas, R, Brown, M D, Jain, Y, Dearnaley, D P, Mason, M D, Gilbert, D, Langley, R E & Millman, R 2023, ' Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol ', Lancet Oncology, vol. 24, no. 5, pp. 443-456 . https://doi.org/10.1016/S1470-2045(23)00148-1
Attard, G, Murphy, L, Clarke, N W, Sachdeva, A, Jones, C, Hoyle, A, Cross, W, Jones, R J, Parker, C C, Gillessen, S, Cook, A, Brawley, C, Gilson, C, Rush, H, Abdel-Aty, H, Amos, C L, Murphy, C, Chowdhury, S, Malik, Z, Russell, J M, Parkar, N, Pugh, C, Diaz-Montana, C, Pezaro, C, Grant, W, Saxby, H, Pedley, I, O'Sullivan, J M, Birtle, A, Gale, J, Srihari, N, Thomas, C, Tanguay, J, Wagstaff, J, Das, P, Gray, E, Alzouebi, M, Parikh, O, Robinson, A, Montazeri, A H, Wylie, J, Zarkar, A, Cathomas, R, Brown, M D, Jain, Y, Dearnaley, D P, Mason, M D, Gilbert, D, Langley, R E & Millman, R 2023, ' Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy : final results from two randomised phase 3 trials of the STAMPEDE platform protocol ', The Lancet. Oncology, vol. 24, no. 5, pp. 443-456 . https://doi.org/10.1016/S1470-2045(23)00148-1

Background: Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we aimed to evaluate long-t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47ca84b5aff90123f3e4082a739e1def
https://doi.org/10.1016/s1470-2045(23)00148-1

Supplementary table ST1 from Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer

Autor: Joe M. O'Sullivan, Sandra Biggart, Conor K. McGarry, Alan R. Hounsell, Kevin M. Prise, Darren Mitchell, Arthur Grey, Aidan Cole, Suneil Jain, Philip G. Turner

Supplementary table ST1 shows adverse events in all domains other than GI, GU and haematological

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dea90baec5db7310fe19215cebfaad8
https://doi.org/10.1158/1078-0432.22480727.v1